Orionis Biosciences
PrivateLast Round
Corporate Funding
May 21, 2025
Total Funding Raised
$111M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Orionis Biosciences operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series C round in October 2022.
Orionis Biosciences is a life sciences company that develops precision therapies for life-threatening diseases using its proprietary Allo-Glue and A-Kine technology platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Orionis Biosciences Comparables
Compare Orionis Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Magnet Biomedicine | 88% | |
| Plexium | 87% | |
| Proxygen | 86% |
For institutional investors. Book with your work email.
Orionis Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | May 21, 2025 | ||||
| Corporate Funding | Sep 20, 2023 | ||||
| Series C | Oct 19, 2022 | ||||
| Convertible Debt | Mar 5, 2020 | ||||
| Series B | Apr 1, 2018 | ||||
Series B | Mar 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Orionis Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cormorant Asset Management | Series C |
| Cascade Investment | Series B |
| Genentech | Corporate Funding |
| Fidelity Management & Research Company | Series B |
| V-Bio Ventures | Series A |
| Excel Venture Management | Series A |
| Nextech Invest | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 155% MoM, reaching 3.8K.
- May 21, 2025
Second multi-year deal valued at over $2 billion for molecular glue development.
For institutional investors. Book with your work email.
Orionis Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Orionis Biosciences's valuation, stock price, and market status.
Is Orionis Biosciences a public or private company?
Orionis Biosciences is a private company.
What is the current stock price of Orionis Biosciences?
Orionis Biosciences is a private company, so its shares have no public market price. Caplight tracks Orionis Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Orionis Biosciences worth (valuation)?
Valuation information for Orionis Biosciences is not publicly available.
Can I buy Orionis Biosciences stock?
Orionis Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Orionis Biosciences's last funding round?
Orionis Biosciences's most recent funding round was Corporate Funding on May 21, 2025.
Who are the main investors in Orionis Biosciences?
Key investors in Orionis Biosciences include Cormorant Asset Management, Genentech, Nextech Invest, Cormorant Asset Management.
Will Orionis Biosciences IPO soon?
No public IPO plans have been announced for Orionis Biosciences.
How can I track Orionis Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Orionis Biosciences's shares on secondary markets.